Evident clinical response to erlotinib as third-line treatment in EGFR FISH (+) male smoker patient with adenocarcinoma of lung

American Journal of Case Reports

Volumn 10, Issue , 2009, Pages 166-171

  Krawczyk, Paweł ^a   Remiszewski, Wojciech ^a   Czekajska Chehab, Elzbieta ^a   Gryglicka, Beata ^a   Warda, Edward ^a   Pelak, Maciej ^a   Wojas Krawczyk, Kamila ^a   Jankowska, Olga ^a   Mazurkiewicz, Tomasz ^a   Milanowski, Janusz ^a,b  

^a MEDICAL UNIVERSITY OF LUBLIN   (Poland)

^b INSTITUTE OF AGRICULTURAL MEDICINE   (Poland)

Author keywords

Clinical response; Erlotinib; Lung adenocarcinoma

Indexed keywords

ANTINEOPLASTIC AGENT; CISPLATIN; DOCETAXEL; EPIDERMAL GROWTH FACTOR RECEPTOR; ERLOTINIB; NAVELBINE; PAMIDRONIC ACID;

ADULT; ANEMIA; ARTICLE; BONE BIOPSY; BONE METASTASIS; BRAIN METASTASIS; CANCER CELL; CANCER RADIOTHERAPY; CANCER REGRESSION; CASE REPORT; COMPUTER ASSISTED TOMOGRAPHY; DISTANT METASTASIS; DRUG ERUPTION; DRUG RESPONSE; DRUG TOLERABILITY; DRUG TREATMENT FAILURE; DYSPNEA; FLUORESCENCE IN SITU HYBRIDIZATION; GENE DOSAGE; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; LIVER METASTASIS; LUNG ADENOCARCINOMA; LYMPH NODE METASTASIS; MALE; MULTIPLE CYCLE TREATMENT; PAPULAR RASH; PROTEIN EXPRESSION; SMOKING; WEIGHT REDUCTION;

EID: 78249250905     PISSN: None     EISSN: 19415923     Source Type: Journal    
DOI: None     Document Type: Article

References (8)

1. Travis WD, Garg K, Franklin WA et al: Bronchioloalveolar carcinoma and lung adenocarcinoma: the clinical importance and research relevance of the 2004 World Health Organization pathologic criteria. J Thorac Oncol, 2006; 1: 13-19
2. Clark GM: Prognostic factors versus predictive factors: examples from a clinical trail of erlotinib. Mol. Oncol, 2007; 1: 406-12
3. Shepherd FA, Rodrigues Pereira J, Ciuleanu T et al: Erlotinib in previously treated non-small-cell lung cancer. N Engl J Med, 2005; 353: 123-32
4. Tsao MS, Sakurada A, Cutz JC et al: Erlotinib in lung cancer - molecular and clinical predictors of outcome. N Engl. J Med, 2006; 355: 133-44
5. Capuzzo F, Hirsh F, Rossi E et al: Epidermal growth factor receptor gene and protein and gefitinib sensitivity in non-small cell lung cancer. J Natl Cancer Inst, 2005; 97: 643-55
6. Florescu M, Hasan B, Seymour L et al: A clinical prognostic index for patients treated with erlotinib in National Cancer Institute of Canada Clinical Trials Group Study BR.21. J Thorac Oncol, 2008; 3: 590-98
7. Kris MG, Giaccone G, Davies A et al: Systemic therapy of bronchioloalveolar carcinoma: results of the first IASLC/ASCO consensus conference on bronchioloalveolar carcinoma. J Thorac Oncol, 2006; 1: 32-36
8. Zhang X, Chang A: Molecular predictors of EGFR-TKI sensitivity in advanced non-small cell lung cancer. Int J Med Sci, 2008; 5: 209-17